SciGen — Shareholder Meeting (November 2002)
18 slides from SciGen's shareholder meeting presentation, November 2002
Slide 1: SciGen Limited Spin-out and ASX Listing
SciGen Limited Spin -out and ASX Listing November 2002 Mark Compton Chief Executive Officer and Managing Director
Slide 2: Introduction
Introduction • SciGen Limited is a bio-pharmaceutical company focussed on the Asia Pacific Region. • The Company has a portfolio of licensed products. • SciGen is incorporated in Singapore. SciGen will trade on the ASX by way of CUFS. • SciGen is being spun-out of Sonic via a Scheme of Arrangement.
Slide 3: Capital Structure
Capital Structure Pre Spin-out Post Spin-out Sonic Healthcare Limited 74% 12% SciTech Genetics Pte Ltd 26% 26% New Shareholders - 62% 100% 100% • New shareholders will hold 1 SciGen share for every Sonic share held. SciGen will have 418,965,443 shares on issue at $0.20 per share. A notional spin-out
Slide 4: Use of Proceeds
Use of Proceeds • The A$30m capital injection by Sonic into SciGen will be utilised as follows: A$(000) Research and Development and Clinical Research 4,700 Regulatory Affairs 1,100 Acquisition of Fixed Assets 1,600 Licence Costs 3,700 Market Development 1,900 General Corporate Purposes 8,900 Costs
Slide 5: Geographic Representation
Geographic Representation • SciGen has business unit representation in the following countries/regions: Minneapolis * * Korea * Hong Kong Vietnam * * Philippines * Singapore * Australia
Slide 6: Product Portfolio
Product Portfolio • SciGen’s product portfolio comprises a range of products. Product Application Estimated World Market $US • Sci-B-Vac 3rd generation hepatitis B vaccine 800M • SciTropin human growth hormone 1600M • SciLin human insulin 2700M • SciFeron Interferon 2b 1800M • SciDaPt-Vac Diphtheria
Slide 7: Sci-B-Vac
Sci-B-Vac • What is Sci-B VacTM ? Sci-B-VacTM is a third generation recombinant hepatitis B vaccine • Immunisation and conditions targeted by Sci-B- VacTM Sci-B-VacTM is a vaccination against hepatitis B. Sci-B-Vac could be used together with anti-viral agents for the treatment of patients with chro
Slide 8: Sci-B-Vac Important features
Sci-B-Vac • Important features – Sci-B-VacTM new proprietary vaccine – Elicits a high antibody response – Response is fast (fewer than three doses) – Highly effective in “non-responder” group – Early data suggests role as a therapeutic vaccine
Slide 9: SciTropin
SciTropin • What is SciTropinTM ? SciTropinTM, is identical to natural human growth hormone. • Diseases and conditions targeted by human growth hormone – Turner’s syndrome – short stature due to pituitary growth hormone deficiency – short stature associated with renal insufficiency – Cachexia in AID
Slide 10: SciLin
SciLin • What is SciLinTM ? SciLinTM is recombinant human insulin. • Diseases and conditions targeted by SciLinTM Insulin is used in treating diabetes. • Advantage Potentially administerable via needle free device (SciTojet), and a price advantage to some extent.
Slide 11: SciFeron
SciFeron • What is SciFeronTM ? SciFeronTM is a highly homogenous, methionine-free recombinant human interferon. • Diseases and conditions are targeted by SciFeronTM Interferon is used in treating virological, oncological and haematological diseases; such as: − Chronic viral hepatitis B AIDS related
Slide 12: Sci-DaPT-Vac
Sci-DaPT-Vac • What is Sci-DaPT-VacTM ? Sci-DaPTTM is a second-generation DaPTTM vaccine licensed from Kaketsuken Institute of Japan. • Diseases and conditions targeted by Sci-DaPTTM The vaccine is designed to be effective against: – Diphtheria – Whooping cough; and – Tetanus • What is Sci-DaPT/HB-V
Slide 13: SciTojet
SciTojet • SciTojet™ - Needle Free Delivery of SciTropin™ and SciLin ™
Slide 14: Timetable for Future Registrations
Timetable for Future Registrations • The anticipated medium term timetable for registration of SciGen’s product portfolio is as follows. Product Country Approval Sci-B-Vac Hong Kong Q2 2003 SciTropin New Zealand Q4 2002 Sci-B-Vac Philippines Approved SciLin India Q4 2002 Sci-B-Vac Singapore Q4 2002
Slide 15: Partners
Partners • SciGen’s major business partners are presented below. Partner Country Bio-Technology General (BTG) USA Peprotech Inc USA Shreya Life Sciences India Akzo Nobel The Netherlands Bioton Poland Ranbaxy Laboratories Limited India Antares Pharma Inc USA & Switzerland Zuellig Pharma Asia
Slide 16: Board of Directors
Board of Directors Paul Freiman BSc, PhMb Chairman Saul Mashaal PhMb, MBA Executive Director & Vice Chairman Dr Colin Goldschmidt MBBCh, FRCPA, FAICD Non-Executive Director Christopher Wilks B Comm, FAICD Non-Executive Director Kenneth Gross CPA, MBA Non-Executive Director Barrie Martin BEc, ANZIIF
Slide 17: Scientific Advisory Board
Scientific Advisory Board Professor Marian Gorecki Israel Ph.D Professor Chan Soh Ha Singapore MBBS, Ph.D Professor Daniel Shouval Israel MD Dr Yitzhak Stabinsky California Ph.D Professor David J Handelsman Sydney MB BS, PH.D, FRACP
Slide 18: SciGen Limited
SciGen Limited Spin -out and ASX Listing November 2002 Mark Compton Chief Executive Officer and Managing Director